Peripheral Artery Disease Market Analysis, Size, Share & Growth Forecast 2026–2034

COMPASS Vascular Low-Dose Rivaroxaban Plus Aspirin 27 Percent Major Adverse Limb Event Reduction and 16 Percent Cardiovascular Event Reduction Has Established the Dual Pathway Inhibition as the Superior PAD Secondary Prevention Over the Aspirin Monotherapy That Prior Guidelines Recommended.Bayer's Xarelto at 2.5 mg twice daily plus aspirin demonstrated 24% reduction in major adverse limb events, myocardial infarction, stroke, and death in COMPASS in stable CAD and PAD, with a 46% reduction in major limb events in the PAD subgroup that is particularly compelling for a disease defined by limb ischaemia. The VOYAGER PAD trial extending dual-pathway inhibition to patients after lower-extremity revascularisation demonstrated 15% reduction in acute limb ischaemia, major amputation, MI, stroke, and cardiovascular death, establishing the regimen as standard of care post-revascularisation. The major amputation reduction in VOYAGER PAD is the most clinically significant outcome for vascular surgeons and interventionalists managing PAD, and the ability to reduce amputation rates through antithrombotic intensification rather than additional revascularisation has changed the post-procedure management paradigm in vascular medicine.

Cilostazol PDE-3 Inhibitor 40 to 60 Percent Claudication Walking Distance Improvement Over Placebo Through Vasodilation and Antiplatelet Activity Has Provided the Pharmacological Claudication Symptom Treatment That Complements the Exercise Rehabilitation That Is First-Line PAD Management.Becton Dickinson's Lutonix drug-coated balloon and Boston Scientific's Eluvia drug-eluting stent demonstrated significantly improved primary patency at 2-3 years compared with plain balloon and bare metal stent controls in LEVANT 2 and IMPERIAL trials, reducing the restenosis that historically required repeat intervention within 1-2 years of conventional angioplasty in the complex femoropopliteal arterial anatomy. The early paclitaxel mortality signal from 2018 Katsanos meta-analysis that halted DCB use has been substantially reassured by 5-year follow-up FDA analysis and additional independent meta-analyses that do not confirm an all-cause mortality excess at device doses used in CE-marked and FDA-approved DCBs. Sirolimus drug-coated balloons from Surmodics are advancing as an alternative limus-based coating that avoids the paclitaxel concerns entirely, and early data from TRANSCEND demonstrates non-inferior patency with a mechanistically distinct antiproliferative agent.

Shockwave Intravascular Lithotripsy Sonic Pressure Wave Calcium Fracture in Heavily Calcified Peripheral Arteries Before Angioplasty Has Enabled the Lumen Gain That Standard Balloon Angioplasty Cannot Achieve Against the Resistant Calcified Plaque That Underdilation Previously Left Untreated.Vascular Biogenics's VB-201 and pluripotent stem cell-derived endothelial cell therapy from companies including Plurilock and RegenMed are advancing Phase 2 programmes in CLTI patients who have exhausted angioplasty and bypass graft options and face amputation as the only alternative. The no-option CLTI population represents approximately 20-30% of all CLTI patients where anatomical complexity of distal occlusive disease precludes conventional revascularisation, creating a high unmet clinical need with no approved pharmacologic alternative beyond wound care and pain management. Hepatocyte growth factor gene therapy VGX-100 and fibroblast growth factor-1 non-viral delivery have shown Phase 2 signals of new vessel formation and wound healing acceleration, but the heterogeneity of response across CLTI patients and the challenge of defining endpoints that capture limb salvage without requiring unrealistically large sample sizes have slowed regulatory progress toward Phase 3 approval.

For related market intelligence, see the Cardiology Drug Market.